Clinical trial
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
NCT02841540 is registered in ClinicalTrials.gov with Hemavant Sciences GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
- Lead sponsor
- Hemavant Sciences GmbH
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 6, 2016
- Completion date
- February 13, 2024
- Enrollment
- 127 (actual)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.